BioSpace News Archive

The Jerome Canady Research Institute for Advanced and Biological Technological Sciences and US Medical Innovations, LLC announced significant positive results from the first FDA Phase I IDE clinical trial for cancer using Canady Helios TM Cold Plasma combined with standard surgical resections at the 2023 American Society of Clinical Oncologists Annual Meeting in Chicago, IL.

TISSIUM, a private medtech specializing in the development of programmable biomorphic polymers for tissue reconstruction, announces it has obtained a non-dilutive financing of €4.2 million from Bpifrance as part of the “France 2030" plan to extend its production capacity for “large volume” syringes.

RK Pharma Inc, a vertically integrated pharmaceutical company announced the successful completion of the acquisition of VGYAAN Pharmaceuticals LLC.

Mustang Bio, Inc. announced that final data from the follicular lymphoma cohort of the single-institution Phase 1/2 clinical trial of MB-106 demonstrate treatment with the CD20-targeted, autologous CAR T-cell therapy resulted in high overall response and complete response rates and CAR T persistence in FL patients.

Beyond Air, Inc. announced that it has entered into an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, LTD. to license the commercial rights for multiple neuronal nitric oxide synthase inhibitor candidates, currently being developed for the treatment of autism spectrum disorder and other neurological conditions.

QIAGEN welcomes the publication of a new, systematic review highlighting the unique value of its proprietary tuberculosis testing technology.

Agile Therapeutics, Inc., a women’s healthcare company, announced that Twirla will become available through FPA Women’s Health.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced that it intends to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering.

PTC Therapeutics, Inc. announced that on June 12, 2023, the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 23 new employees.

Hepion Pharmaceuticals, Inc. announced that two abstracts have been accepted for poster presentations at the European Association for the Study of the Liver International Liver Congress™ 2023 taking place June 21 - 24, 2023 in Vienna, Austria and digitally.